PRLD — Prelude Therapeutics Incorporated Share News
0.000.00%
Last trade - 00:00- $236.22m
- $84.47m
- $12.14m
Brief: Prelude Therapeutics FY Net Income USD -121.832 Million
Brief: Prelude Therapeutics Announces $25 Million Private Placement
Brief: Prelude Therapeutics Q3 EPS USD -0.45
Prelude Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Prelude Therapeutics Announces Second Quarter 2023 Financial Results And Provides Corporate Update
Brief: Prelude Therapeutics, Inc. posts Q2 EPS USD -0.54
U.S. STOCKS ON THE MOVE-Brady, Madison Square Garden Entertainment, Bowlero
U.S. STOCKS ON THE MOVE-Hawkins, Netflix, Alibaba Group
U.S. STOCKS ON THE MOVE-Dole, Canada Goose, Regency Centers
Prelude Therapeutics drops on pricing $100 mln equity offering
Brief: Prelude Therapeutics Announces Launch Of Proposed Public Offering
Prelude Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Prelude Therapeutics Inc Anticipates Existing Cash Will Fund Operations Into Q4 Of 2024
Prelude Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
Brief: Prelude Therapeutics Inc - On March 15, Co Entered Into An Open Market Sale Agreement With Jefferies Llc
Prelude Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Prelude Therapeutics Reports Full-Year 2022 Financial Results
Prelude Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview
Prelude Therapeutics Inc reports results for the quarter ended in September - Earnings Summary